NCT00633295View on ClinicalTrials.gov

Phase II Study Aiming to Evaluate the Efficacy and Safety of Nilotinib Patients With Gastrointestinal Stromal Tumors (GIST) Resistant or Intolerant to Imatinib and or to 2nd Line Tyrosine Kinas (TK) Inhibitor

PHASE2CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

May 31, 2010

Study Completion Date

May 31, 2010

Conditions
Gastrointestinal Stromal Tumors (GIST)
Interventions
DRUG

AMN107- NILOTINIB

The dose of nilotinib will be 400 mg bid.

Trial Locations (3)

Unknown

Novartis Investigative Site, Jerusalem

Novartis Investigative Site, Tel Aviv

Novartis Investigative Site, Tel Litwinsky

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY